Other

AHA 2020 | EMPATROPISM: Empagliflozin in Non-Diabetics with Cardiac Failure

Empagliflozin improves cardiac function, exercise capacity and quality of life in non-diabetic patients with cardiac failure and...

AHA 2020 | POLYPILL: One Pill Plus Aspirin to Treat Everything

Using only one compressed tablet or pill with a fixed combination of statins, angiotensin-converting enzyme inhibitors, beta-blockers,...

AHA 2020 | AFFIRM-AHF: Ferric Carboxymaltose and Fewer Hospitalizations for Cardiac Failure

Correcting iron deficiency in patients with cardiac failure might reduce the risk of new hospitalizations according to...

AHA 2020 | Statins: Confirmed Benefits for the Elderly

Elderly patients (>70) with high cholesterol levels have been systematically excluded from randomized studies on statins, despite...

What Is the Healthiest Diet?

This review published in JACC focuses on the foods we shood consume rather than the foods we...

ESC 2020 | Antihypertensive Therapy Reduces Events Regardless of BP Levels or Risk

Antihypertensive therapy reduces the risk of cardiovascular events even in patients with no history of heart disease...

ESC 2020 | More Evidence on Colchicine for Chronic Ischemic Heart Disease

According to this new study, colchicine offers some benefit to patients with chronic ischemic heart disease. Similar...

ESC 2020 | Dapagliflozin in Kidney Failure: The Drug Continues to Conquer Other Territories

The DAPA-CKD trial has shown dapagliflozin, a SGLT2 receptor inhibitor, improves function, and reduces cardiovascular events and...